avapritinib (Ayvakit)
Jump to navigation
Jump to search
Indications
- unresectable or metastatic gastrointestinal stromal tumor (GIST) with a PDGFRA exon 18 mutation, including D842V mutations[1]
* 5=10% of GISTs have a PDGFRA mutation[3]
Dosage
* at least 1 hour before or 2 hours after a meal.
Adverse effects
- > 20%
- edema, nausea, fatigue/asthenia, cognitive impairment, vomiting, decreased appetite, diarrhea, hair color changes, increased lacrimation, abdominal pain, constipation, rash, dizziness
Mechanism of action
- tyrosine kinase inhibitor, inhibits PDGFRA[3]
More general terms
References
- ↑ 1.0 1.1 FDA Drug Approvals Jan 10, 2020 FDA approves avapritinib for gastrointestinal stromal tumor with a rare mutation
- ↑ Wikipedia: Avapritinib https://en.wikipedia.org/wiki/Avapritinib
- ↑ 3.0 3.1 3.2 American Cancer Society. Jan 10, 2020 FDA Approves Ayvakit (Avapritinib) for GIST. https://www.cancer.org/latest-news/fda-approves-ayvakit-avapritinib-for-gist.html